Comments for Ethics, Technology and Society

Comment on Government to Review Pfizer CIHR Appointment by Guest

Guest — Fri, 04 Dec 2009 21:17:48 +0000

Surely the issue is not about Pfizer reps specifically on the CIHR governing board.?

I feel the issue is more about a conflict of interest between the appointment of ANY member of the pharmaceutical industry to a publicly-funded body that directs the health research agenda for Canada. Pfizer, GSK, Merck … all would be problematic, as all have private-sector interests.

Comment on Pfizer VP Appointed to CIHR Governing Board by Jason Millar

Jason Millar — Wed, 25 Nov 2009 14:10:32 +0000

I take your point regarding the market/business experience. My understanding is that the board is required (though maybe in a loose sense) to have the kind of expertise he brings to bear.
However, I have to echo Downie's concerns about the choice of a Pfizer exec. Pfizer has recently been found guilty of very serious ethical transgressions, having to do particularly with the manner in which they conduct their research (e.g. misleadingly manipulating results to make their drugs appear useful when the data does not support it), and bring their drugs to market (e.g. suggesting they be prescribed for "off-label" uses). These types of transgressions relate directly to the very specific qualifications that an industry representative would be asked to provide to the board.

Given that Pfizer's track record is highly dubious in that regard, it seems a better appointment would have come from another industry leader.

Comment on Pfizer VP Appointed to CIHR Governing Board by Michael Karlin

Michael Karlin — Wed, 25 Nov 2009 13:58:56 +0000

It's not as contrversial as it seems. He is one vote of 17, and adds some element of market expertise to the group. Most of the Governing Council are university professors/researchers, so he can be resoundly overruled by his colleagues were he to get too out of line. As well, I believe the Scientific Council makes decisions on research ethics; the GC makes strategic decisions and decisions related to corporate infrasturcture and finance, so his effect on the conduct of research will be minimal.

This is just my own political philosophy, but I think it is helpful to have a variety of viewpoints around the table of such a notable research funder.